These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33497941)

  • 1. Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase.
    Alswied A; Rehman A; Lai LW; Duran J; Sardar M; Proytcheva MA
    Cancer Genet; 2021 Apr; 252-253():111-114. PubMed ID: 33497941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
    Crisan AM; Coriu D; Arion C; Colita A; Jardan C
    J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia.
    Wasilewska EM; Panasiuk B; Gniot M; Sawicka A; Kozłowska K; Lewandowski K; Kłoczko J; Midro AT
    Cancer Genet; 2017 Oct; 216-217():1-9. PubMed ID: 29025581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
    Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
    Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
    Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
    Bozkurt S; Uz B; Buyukasik Y; Bektas O; Inanc A; Goker H; Kansu E
    Med Oncol; 2013 Mar; 30(1):443. PubMed ID: 23292838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.
    Asnafi AA; Deris Zayeri Z; Shahrabi S; Zibara K; Vosughi T
    J Cell Physiol; 2019 May; 234(5):5798-5806. PubMed ID: 30430567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
    Hackanson B; Rückert A; Lübbert M
    Eur J Haematol; 2009 Dec; 83(6):611-2. PubMed ID: 19682063
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of Ph
    Ansari S; Verma M
    Med Oncol; 2023 Jul; 40(8):237. PubMed ID: 37439908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy.
    Zhu H; Yang B; Liu J; Wu W; Ling Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18888. PubMed ID: 32011516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
    Fabarius A; Leitner A; Hochhaus A; Müller MC; Hanfstein B; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Reiter A; Jung-Munkwitz S; Proetel U; Schwaab J; Hofmann WK; Schubert J; Einsele H; Ho AD; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Lauseker M; Pfirrmann M; Hasford J; Saussele S; Hehlmann R;
    Blood; 2011 Dec; 118(26):6760-8. PubMed ID: 22039253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Wang W; Cortes JE; Tang G; Khoury JD; Wang S; Bueso-Ramos CE; DiGiuseppe JA; Chen Z; Kantarjian HM; Medeiros LJ; Hu S
    Blood; 2016 Jun; 127(22):2742-50. PubMed ID: 27006386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
    Navarro JT; Feliu E; Grau J; Espinet B; Colomer D; Ribera JM; Oriol A; Granada I; Juncà J; Millá F
    Am J Hematol; 2007 Sep; 82(9):849-51. PubMed ID: 17563075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
    Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
    Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
    Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
    Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
    Zaccaria A; Valenti AM; Donti E; Gozzetti A; Ronconi S; Spedicato F
    Haematologica; 2007 Apr; 92(4):564-5. PubMed ID: 17488671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.
    Phan TX; Hoang AV; Huynh VM; Nguyen KT; Nguyen TB; Huynh N; Pham QT; Tran VB; Tran VB; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jul; 168(1):59-68. PubMed ID: 16772122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
    Johansson B; Fioretos T; Mitelman F
    Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion (7)(p11p15) in a patient with Philadelphia-positive chronic myelogenous leukemia.
    Carrasco Juan JL; Otero Gómez A; García Miranda JL; Trujillo González M; Herrera Fernández M; Bello Hernández T
    Cancer Genet Cytogenet; 1992 Dec; 64(2):142-4. PubMed ID: 1486563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.